ERI3

Across TCGA pan-cancer cohorts, ERI3 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated ERI3 data layer compared with 20 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher ERI3 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ERI3 expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

HNSC, LUAD, and CCRCC are the cancer types where ERI3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	IV	0.566	0.840	.007	31	view →
LUAD	OS	Median	III,IV	0.670	0.219	.007	14	view →
CCRCC	OS	Median	IV	0.451	1.000	.016	13	view →
UCEC	OS	Median	II,III,IV	0.565	1.000	.004	8	view →
GBM	DFS	Tertile	All	0.573	0.823	.022	3	view →
PDAC	OS	Median	IV	0.491	0.836	.024	3	view →
LSCC	DFS	Median	III,IV	0.874	1.000	.033	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

ERI3–HNSC (DFS)

Open the HNSC breakdown →